CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines The Objective Physical Activity and Cardiovascular Disease Health in Older Women (OPACH) Study 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial Circadian-Regulated Cell Death in Cardiovascular Diseases Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes

Original Research2019 Aug 7;40(30):2482-2491.

JOURNAL:Eur Heart J. Article Link

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis

Vromman A, Ruvkun V, Shvartz E et al. Keywords: arterial remodelling; atherosclerosis; inflammation; interleukin-1

ABSTRACT


AIMS - Targeting interleukin-1 (IL-1) represents a novel therapeutic approach to atherosclerosis. CANTOS demonstrated the benefits of IL-1β neutralization in patients post-myocardial infarction with residual inflammatory risk. Yet, some mouse data have shown a prominent role of IL-1α rather than IL-1β in atherosclerosis, or even a deleterious effect of IL-1 on outward arterial remodelling in atherosclerosis-susceptible mice. To shed light on these disparate results, this study investigated the effect of neutralizing IL-1α or/and IL-1β isoforms starting either early in atherogenesis or later in ApoE-/- mice with established atheroma.


METHODS AND RESULTS - The neutralization of IL-1α or of both IL-1 isoforms impaired outward remodelling during early atherogenesis as assessed by micro-computed tomographic and histologic assessment. In contrast, the neutralization of IL-1β did not impair outward remodelling either during early atherogenesis or in mice with established lesions. Interleukin-1β inhibition promoted a slant of blood monocytes towards a less inflammatory state during atherogenesis, reduced the size of established atheromata, and increased plasma levels of IL-10 without limiting outward remodelling of brachiocephalic arteries.


CONCLUSION - This study established a pivotal role for IL-1α in the remodelling of arteries during early experimental atherogenesis, whereas IL-1β drives inflammation during atherogenesis and the evolution of advanced atheroma in mice.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019.